The prognostic significance of JAML and its role in remodeling the immune microenvironment via the cGAS-STING pathway in endometrial cancer
Authors:
Open Access
- 29 January 2026
- journal article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17
Abstract
Background: Endometrial cancer (EC) is a major gynecological malignancy with a poor prognosis in the advanced stages. Junctional adhesion molecule-like protein (JAML) is gaining attention in cancer biology; however, its role in EC remains unclear. Methods: This study integrated multi-omics data (TCGA, pan-cancer analysis and single-cell transcriptomics), dual independent clinical cohorts (TCGA dataset and an institutional cohort), and in vitro / in vivo experimental models to systematically analyze JAML expression patterns, clinical relevance, and tumor-progression regulatory mechanisms in EC. Experimental approaches included: immunohistochemistry (IHC), qRT-PCR, and Western blotting for expression validation; shRNA knockdown, Transwell/scratch assays, CCK-8 assays, and conditioned medium co-culture models for functional analysis; bioinformatics tools (ESTIMATE, TIMER, MCP-counter) and flow cytometry for immune microenvironment evaluation; drug sensitivity analysis (Genomics of Drug Sensitivity in Cancer (GDSC)/Tumor Immune Dysfunction and Exclusion (TIDE) databases) and prognostic modeling (Cox regression/nomogram) for clinical application assessment. Results: In EC, JAML expression was significantly downregulated and correlated with poor prognosis. JAML knockdown promoted cancer cell proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) (all P < 0.01), accompanied by reduced stimulator of interferon genes (STING) phosphorylation (P < 0.01). Low JAML expression correlated with decreased M1 (CD86 + , P < 0.01) and increased M2 (CD206 + , P < 0.01) macrophage infiltration. It was also linked to reduced cisplatin/paclitaxel sensitivity (P < 0.05) and lower immunotherapy response (29.04% vs. 45.05%, P = 0.015). STING agonist cyclic GMP–AMP (cGAMP) partially restored M1 infiltration and chemosensitivity after JAML knockdown in vitro . A nomogram incorporating JAML and clinicopathological parameters showed improved predictive performance (AUC 0.885; cutoff 0.882; sensitivity 0.818, specificity 0.820), with calibration curves confirming good agreement between predicted and observed recurrence. Conclusions: These findings suggest that JAML deficiency may suppress cyclic GMP-AMP synthase (cGAS)-STING pathway activation, potentially contributing to M1/M2 macrophage polarization imbalance and facilitating EC progression. Clinically, JAML expression shows promise as a potential biomarker for prognostic stratification and treatment response prediction (chemotherapy/immunotherapy), providing insights for developing precision immunochemotherapy strategies in EC.Keywords
Funding Information
- Natural Science Foundation of Chongqing Municipality (CSTB2024NSCQ-MSX1240)
- China Postdoctoral Science Foundation (2024M753872)
This publication has 57 references indexed in Scilit:
- Mechanism of Sijunzi Decoction in the treatment of colorectal cancer based on network pharmacology and experimental validationJournal of Ethnopharmacology, 2022
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- Endometrial cancerThe Lancet, 2022
- Downregulation of HOXA11 enhances endometrial cancer malignancy and cisplatin resistance via activating PTEN/AKT signaling pathwayClinical and Translational Oncology, 2021
- Understanding the tumor microenvironment for effective immunotherapyMedicinal Research Reviews, 2020
- IL-24 inhibits endometrial cancer cell proliferation by promoting apoptosis through the mitochondrial intrinsic signaling pathwayBiomedicine & Pharmacotherapy, 2020
- Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid TumorsAdvances in Therapy, 2019
- Revised FIGO staging for carcinoma of the vulva, cervix, and endometriumInternational Journal of Gynecology & Obstetrics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Endometrial cancerThe Lancet, 2005